Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
Glucotrack (Nasdaq: GCTK) has appointed Peter C. Wulff as Chief Financial Officer, effective immediately. Wulff brings over 35 years of financial management experience in the emerging growth life sciences sector, with expertise in both public and private companies.
Wulff's track record includes successful capital raising through public and private equity offerings, debt financing, and strategic business transactions. He previously served as CFO at Biological Dynamics, Inc. and JenaValve Technology, Inc., where he managed the company's corporate relocation from Germany and various capital raise transactions. His experience also includes financial leadership roles at Alphatec Spine Holdings, Artes Medical, CryoCor, and Pure Biosciences.
The appointment aims to support Glucotrack's commercialization of its continuous blood glucose monitor for people with diabetes, with focus on driving financial excellence and advancing the company's strategic vision.
Glucotrack (Nasdaq: GCTK) ha nominato Peter C. Wulff come Chief Financial Officer, con effetto immediato. Wulff porta con sé oltre 35 anni di esperienza nella gestione finanziaria nel settore delle scienze della vita in fase di crescita, con competenze sia in aziende pubbliche che private.
Il percorso di Wulff include un bilancio di successo nel reperimento di capitali attraverso offerte di equity pubbliche e private, finanziamenti tramite debito e transazioni commerciali strategiche. Ha precedentemente ricoperto il ruolo di CFO presso Biological Dynamics, Inc. e JenaValve Technology, Inc., dove ha gestito il trasferimento dell'azienda dalla Germania e numerose transazioni di raccolta fondi. La sua esperienza comprende anche ruoli di leadership finanziaria in Alphatec Spine Holdings, Artes Medical, CryoCor e Pure Biosciences.
La nomina mira a supportare la commercializzazione del monitor continuo della glicemia di Glucotrack per le persone con diabete, concentrandosi sull'eccellenza finanziaria e sul progresso della visione strategica dell'azienda.
Glucotrack (Nasdaq: GCTK) ha designado a Peter C. Wulff como Director Financiero, con efecto inmediato. Wulff aporta más de 35 años de experiencia en gestión financiera en el sector de ciencias de la vida en crecimiento, con experiencia en empresas tanto públicas como privadas.
Su historial incluye el éxito en la captación de capital a través de ofertas de acciones públicas y privadas, financiamiento de deuda y transacciones comerciales estratégicas. Anteriormente, fue CFO en Biological Dynamics, Inc. y JenaValve Technology, Inc., donde gestionó la reubicación corporativa de la empresa desde Alemania y varias transacciones de recaudación de capital. Su experiencia también abarca roles de liderazgo financiero en Alphatec Spine Holdings, Artes Medical, CryoCor y Pure Biosciences.
La designación tiene como objetivo apoyar la comercialización del monitor continuo de glucosa en sangre de Glucotrack para personas con diabetes, con un enfoque en impulsar la excelencia financiera y avanzar en la visión estratégica de la empresa.
글루코트랙 (Nasdaq: GCTK)은 피터 C. 울프를 최고재무책임자(CFO)로 즉시 임명했습니다. 울프는 35년 이상의 금융 관리 경험을 갖추고 있으며, 성장 단계의 생명 과학 분야에서 공공 및 민간 기업 모두에서 Expertise를 보유하고 있습니다.
울프의 경력에는 공공 및 민간 자본 조달, 부채 금융 및 전략적 비즈니스 거래를 통한 성공적인 자본 조달이 포함됩니다. 그는 이전에 Biological Dynamics, Inc.와 JenaValve Technology, Inc.의 CFO로 근무하며 독일에서 기업 이사를 관리하고 다양한 자본 조달 거래를 진행했습니다. 그의 경험에는 Alphatec Spine Holdings, Artes Medical, CryoCor 및 Pure Biosciences에서의 금융 리더십 역할도 포함됩니다.
이번 임명은 당뇨병 환자를 위한 지속적인 혈당 모니터의 상용화를 지원하려는 목적을 가지고 있으며, 재무 우수성을 높이고 회사의 전략적 비전을 발전시키는 데 중점을 두고 있습니다.
Glucotrack (Nasdaq: GCTK) a nommé Peter C. Wulff au poste de Directeur Financier, prenant effet immédiatement. Wulff apporte plus de 35 ans d'expérience en gestion financière dans le secteur des sciences de la vie en pleine croissance, avec une expertise dans des entreprises publiques et privées.
Le parcours de Wulff inclut des réussites dans la levée de fonds par le biais d'offres d'actions publiques et privées, de financements par emprunt et de transactions commerciales stratégiques. Il a précédemment été CFO chez Biological Dynamics, Inc. et JenaValve Technology, Inc., où il a géré la réinstallation de l'entreprise depuis l'Allemagne et diverses transactions de levée de fonds. Son expérience comprend également des rôles de leadership financier chez Alphatec Spine Holdings, Artes Medical, CryoCor et Pure Biosciences.
Cette nomination vise à soutenir la commercialisation du moniteur de glucose sanguin continu de Glucotrack pour les personnes atteintes de diabète, en mettant l'accent sur l'excellence financière et la réalisation de la vision stratégique de l'entreprise.
Glucotrack (Nasdaq: GCTK) hat Peter C. Wulff mit sofortiger Wirkung zum Chief Financial Officer ernannt. Wulff bringt über 35 Jahre Erfahrung im Finanzmanagement im aufstrebenden Wachstumssektor der Lebenswissenschaften mit, mit Fachkenntnissen in sowohl öffentlichen als auch privaten Unternehmen.
Wulffs Erfolgsbilanz umfasst die erfolgreiche Kapitalbeschaffung durch öffentliche und private Aktienangebote, die Finanzierung von Schulden und strategische Geschäftstransaktionen. Zuvor war er CFO bei Biological Dynamics, Inc. und JenaValve Technology, Inc., wo er den Unternehmensumzug aus Deutschland und verschiedene Kapitalbeschaffungsmaßnahmen leitete. Zu seinen Erfahrungen gehören auch Führungspositionen im Finanzbereich bei Alphatec Spine Holdings, Artes Medical, CryoCor und Pure Biosciences.
Die Ernennung zielt darauf ab, die Kommerzialisierung von Glucotracks kontinuierlichem Blutzuckermonitor für Menschen mit Diabetes zu unterstützen, mit dem Fokus auf finanzielle Exzellenz und die Weiterentwicklung der strategischen Vision des Unternehmens.
- Appointment of seasoned CFO with 35+ years of financial management experience
- Strong track record in capital raising through various financial mechanisms
- Extensive experience in life sciences sector and medical technology companies
- Expertise in managing corporate growth and international operations
- None.
Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes
RUTHERFORD, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that Peter C. Wulff has been named Chief Financial Officer, effective immediately.
Mr. Wulff has over 35 years of financial management experience in both public and privately held companies in the emerging growth life sciences sector. He has a strong track record of successfully raising capital through a variety of mechanisms including public and private equity offerings, debt financing, and strategic business transactions. Mr. Wulff most recently served as Chief Financial Officer at Biological Dynamics, Inc. Prior to that, he served as Chief Financial Officer at JenaValve Technology, Inc., where he played an instrumental role in the corporate relocation from Germany and subsequent growth of its US operations, including managed closing of various capital raise transactions, including equity, debt and international out-licensing of intellectual property. Prior to JenaValve, Mr. Wulff served as the financial corporate officer for medical technology companies including Alphatec Spine Holdings, Artes Medical, CryoCor and Pure Biosciences.
“I look forward to working with the Glucotrack team to commercialize this revolutionary technology, drive financial excellence and support the long-term strategic vision of the Company,” said Mr. Wulff.
“Peter has an exceptional track record of delivering results and creating value and is uniquely qualified to lead our finance and accounting organization into the next phase of growth,” said Paul V. Goode, PhD, President and CEO of Glucotrack. “His extensive experience in capital markets and strategic planning will be invaluable as we advance our novel continuous blood glucose monitor through clinical development and prepare for future commercialization.”
For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2024.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
Who is the new CFO appointed by Glucotrack (GCTK) in January 2024?
What is Peter Wulff's experience before joining Glucotrack (GCTK)?
What is Glucotrack's (GCTK) main product under development?
What are Peter Wulff's main responsibilities at Glucotrack (GCTK)?
